Jacobs & Co. CA Raises Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Jacobs & Co. CA increased its position in Edwards Lifesciences Co. (NYSE:EW) by 3.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,665 shares of the medical research company’s stock after buying an additional 3,447 shares during the period. Jacobs & Co. CA’s holdings in Edwards Lifesciences were worth $8,438,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of EW. Castleview Partners LLC purchased a new stake in Edwards Lifesciences in the first quarter valued at approximately $25,000. Compass Wealth Management LLC acquired a new position in Edwards Lifesciences during the fourth quarter valued at approximately $31,000. Jackson Grant Investment Advisers Inc. purchased a new stake in Edwards Lifesciences during the third quarter worth approximately $38,000. Janiczek Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 108.6% during the 3rd quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 303 shares in the last quarter. Finally, Operose Advisors LLC increased its holdings in Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $72.98, for a total transaction of $2,141,963.00. Following the transaction, the director now directly owns 4,486 shares in the company, valued at $327,388.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $72.98, for a total transaction of $2,141,963.00. Following the completion of the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at approximately $327,388.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 14,500 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $91.01, for a total transaction of $1,319,645.00. Following the sale, the vice president now directly owns 39,503 shares in the company, valued at $3,595,168.03. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 196,859 shares of company stock worth $16,445,296. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $95.15 on Thursday. The company has a market cap of $57.21 billion, a P/E ratio of 41.37, a P/E/G ratio of 4.63 and a beta of 1.05. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $95.35. The business’s 50 day moving average is $85.48 and its two-hundred day moving average is $75.86. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business’s revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm posted $0.64 EPS. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on EW shares. Wells Fargo & Company raised shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective for the company in a research report on Friday, February 2nd. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday. Evercore ISI lowered shares of Edwards Lifesciences from an “outperform” rating to an “in-line” rating and cut their price objective for the stock from $80.00 to $77.00 in a report on Thursday, January 4th. Stifel Nicolaus raised their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research note on Wednesday, February 7th. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and a consensus price target of $88.50.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.